{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:37:43Z","timestamp":1789623463123,"version":"build-2803163510"},"reference-count":30,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2026,8,24]]},"DOI":"10.1080\/10428194.2026.2682293","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T17:23:06Z","timestamp":1780852986000},"page":"2057-2063","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Chimeric antigen receptor T-cell therapy induces complete remission in a patient with concurrent CLL with CNS involvement and multiple sclerosis"],"prefix":"10.1080","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9219-2655","authenticated-orcid":false,"given":"Dermot J.","family":"Murphy","sequence":"first","affiliation":[{"name":"University of Vermont Cancer Center, University of Vermont Larner College of Medicine","place":["Burlington, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siba","family":"El Hussein","sequence":"additional","affiliation":[{"name":"University of Vermont Cancer Center, University of Vermont Larner College of Medicine","place":["Burlington, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Applebee","sequence":"additional","affiliation":[{"name":"St. Peters Health Partners","place":["Albany, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Thomas","sequence":"additional","affiliation":[{"name":"University of Vermont Cancer Center, University of Vermont Larner College of Medicine","place":["Burlington, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James N.","family":"Gerson","sequence":"additional","affiliation":[{"name":"University of Vermont Cancer Center, University of Vermont Larner College of Medicine","place":["Burlington, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,7]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27546"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.136556"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3329-2"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01052-8"},{"key":"e_1_3_3_6_1","unstructured":"FDA Approves Liso-cel the First and Only CAR-T for CLL\/SLL. California: CLL Society March; 2024. https:\/\/cllsociety.org\/2024\/03\/fda-approves-liso-cel-the-first-and-only-car-t-for-cll-sll\/"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.3818"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.8519"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-201809"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2856"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0602-x"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200840"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200339"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004106"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014738"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27316"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.693200"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01508-3"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.20234"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.10.024"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1188049"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2508023"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00140-6"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00498-5"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104222"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.03.002"},{"key":"e_1_3_3_31_1","unstructured":"KYSA-7: A study of anti-CD19 CAR T-cell therapy in subjects with refractory primary and secondary progressive multiple sclerosis. Maryland: ClinicalTrials.gov; 2025. https:\/\/clinicaltrials.gov\/study\/NCT06384976"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2026.2682293","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/10428194.2026.2682293","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2026.2682293","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:07:48Z","timestamp":1787850468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2026.2682293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,7]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,8,24]]}},"alternative-id":["10.1080\/10428194.2026.2682293"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2026.2682293","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}